Mark Milton

Company: Lake Boon Pharmaceutical Consulting

Job title: Principal

Bio:

Mark retired in 2022 after 31 years in the Pharmaceutical Industry, most recently working for Novartis where he provided support to biodistribution and immunogenicity assessments for Gene Therapies.

Seminars:

Detecting Pre-Existing Antibodies to AAV Gene Therapies 11:00 am

One of the inherent challenges to effective AAV gene therapy treatment is the prior exposure and neutralizing antibody (NAb) generation in a large number of target populations. The methods used for testing for seropositivity prior to transfer remains a hotly-debated topic, with no universal test or titer currently deployed as an industry standard for detecting…Read more

day: Pre-Conference Day